Surotomycin
Surotomycin is an investigational antibiotic that was under development by Cubist Pharmaceuticals, a subsidiary of Merck & Co.. It is a cyclic lipopeptide that was being developed for the treatment of Clostridium difficile infection (CDI). However, the development of Surotomycin was discontinued in 2016 after it failed to show superiority over vancomycin in Phase III clinical trials.
History
Surotomycin was first synthesized by Cubist Pharmaceuticals, a company known for its focus on research and development of antibiotics to treat serious infections. The development of Surotomycin was part of the company's efforts to combat the growing problem of antibiotic resistance.
In 2014, Cubist Pharmaceuticals was acquired by Merck & Co., a multinational pharmaceutical company. Following the acquisition, the development of Surotomycin continued under the new ownership.
Mechanism of Action
Surotomycin is a cyclic lipopeptide, a class of antibiotics that work by disrupting the bacterial cell membrane. It is bactericidal, meaning it kills bacteria rather than merely inhibiting their growth. Surotomycin specifically targets Clostridium difficile, a bacterium that can cause severe diarrhea and life-threatening inflammation of the colon.
Clinical Trials
Surotomycin underwent Phase I, II, and III clinical trials. The Phase III trials, however, did not show Surotomycin to be superior to vancomycin, a currently used treatment for CDI. As a result, Merck & Co. decided to discontinue the development of Surotomycin in 2016.
Future
Despite the discontinuation of Surotomycin, research into new treatments for CDI continues. The failure of Surotomycin underscores the challenges of developing new antibiotics and the importance of ongoing research in this area.
| Merck & Co., Inc. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Cubist Pharmaceuticals | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This Cubist Pharmaceuticals related article is a stub.
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
